We’re the leading resource for those affected by bleeding disorders. You can count on our organization to ensure your voice is heard. It’s with your help that we can make a difference. Learn more and get involved.
December 15th is the deadline to enroll in or change plans for coverage starting January 1, 2017. Take time to review your coverage today.
You helped My Life, Our Future, the genotyping initiative, reach a milestone in hemophilia research.
Imagine being able to pop a few capsules in your mouth and be protected from bleeds the way infusions now do. That’s the goal of investigators in the Cockrell School of Engineering at The University of Texas at Austin.
The new oral delivery system uses micro- and nanoparticles to carry a protein therapy that treats hemophilia B, or factor IX deficiency. The findings were published in the November 30 issue of the International Journal of Pharmaceutics.
Imagine being able to pop a few capsules in your mouth and be protected from bleeds the way infusions now do.
WILATE®, a human-derived von Willebrand factor/coagulation factor VIII therapy, will be used in two upcoming clinical trials slated to launch in December 2016.